Gsa Capital Partners LLP Kezar Life Sciences, Inc. Transaction History

Gsa Capital Partners LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$0.8 - $1.05 $17,750 - $23,297	22,188 Added 8.52%	282,595 $254,000
Q4 2023 Feb 16, 2024	BUY	$0.72 - $1.15 $187,493 - $299,468	260,407 New	260,407 $247,000
Q1 2023 May 12, 2023	BUY	$3.13 - $7.31 $305,606 - $713,733	97,638 New	97,638 $305,000
Q3 2022 Nov 14, 2022	BUY	$7.99 - $10.75 $138,754 - $186,684	17,366 Added 68.57%	42,691 $368,000
Q2 2022 Aug 09, 2022	BUY	$4.58 - $17.13 $115,988 - $433,817	25,325 New	25,325 $209,000
Q3 2021 Nov 12, 2021	SELL	$4.85 - $9.73 $431,257 - $865,181	-88,919 Closed	0 $0
Q2 2021 Aug 05, 2021	SELL	$4.93 - $6.46 $17,797 - $23,320	-3,610 Reduced 3.9%	88,919 $483,000
Q1 2021 May 10, 2021	SELL	$5.24 - $6.99 $94,802 - $126,463	-18,092 Reduced 16.35%	92,529 $551,000
Q4 2020 Feb 03, 2021	BUY	$4.77 - $6.58 $228,029 - $314,556	47,805 Added 76.1%	110,621 $577,000
Q3 2020 Nov 06, 2020	BUY	$4.36 - $5.5 $273,877 - $345,488	62,816 New	62,816 $304,000
Q4 2019 Feb 12, 2020	SELL	$2.5 - $4.26 $105,927 - $180,500	-42,371 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$3.0 - $7.58 $127,113 - $321,172	42,371 New	42,371 $139,000

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $430M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.